How Ligands Illuminate GPCR Molecular Pharmacology

Slides:



Advertisements
Similar presentations
G Protein Linked Receptors
Advertisements

Chap. 15 Problem 2 Signaling systems are classified based on the distance over which they act. Endocrine signaling acts over long distances within the.
Crystal Structure of an LSD-Bound Human Serotonin Receptor
AMPK—Sensing Energy while Talking to Other Signaling Pathways
Transmembrane and GPCR Mohammed Mohammed Khan PhD Scholar- Department of Biochemistry King Abdul-Aziz University.
Volume 21, Issue 12, Pages (December 2013)
Volume 19, Issue 8, Pages (August 2011)
Volume 41, Issue 6, Pages (March 2011)
Arvin C. Dar, Michael S. Lopez, Kevan M. Shokat  Chemistry & Biology 
Fulvia Bono, Judith Ebert, Esben Lorentzen, Elena Conti  Cell 
Structure of an LDLR-RAP Complex Reveals a General Mode for Ligand Recognition by Lipoprotein Receptors  Carl Fisher, Natalia Beglova, Stephen C. Blacklow 
Volume 17, Issue 12, Pages (December 2009)
M.J. Rebecchi, S.N. Pentyala  British Journal of Anaesthesia 
GPCR and heterotrimeric G-protein signalling.
Volume 124, Issue 2, Pages (January 2006)
The Rational Design of an AIDS Vaccine
Chaperone-Assisted Crystallography with DARPins
Supriyo Bhattacharya, Nagarajan Vaidehi  Biophysical Journal 
From Promiscuity to Precision: Protein Phosphatases Get a Makeover
Volume 26, Issue 1, Pages e2 (January 2018)
Volume 20, Issue 5, Pages (May 2012)
The Mechanism of E. coli RNA Polymerase Regulation by ppGpp Is Suggested by the Structure of their Complex  Yuhong Zuo, Yeming Wang, Thomas A. Steitz 
Choel Kim, Cecilia Y. Cheng, S. Adrian Saldanha, Susan S. Taylor  Cell 
Allostery in Disease and in Drug Discovery
Volume 17, Issue 3, Pages (March 2009)
Volume 26, Issue 3, Pages (May 2007)
The Ribosome Emerges from a Black Box
Volume 69, Issue 5, Pages e5 (March 2018)
RAS Proteins and Their Regulators in Human Disease
HLA-F: A New Kid Licensed for Peptide Presentation
DREADDs for Neuroscientists
AKT/PKB Signaling: Navigating the Network
Volume 90, Issue 1, Pages (July 1997)
Volume 5, Issue 1, Pages 1-2 (July 2003)
The HETE Is on FFAR1 and Pancreatic Islet Cells
Volume 33, Issue 2, Pages (January 2009)
Volume 24, Issue 6, Pages (June 2016)
Structural Basis of EZH2 Recognition by EED
Volume 42, Issue 1, Pages 9-22 (April 2011)
A Drug-Drug Interaction Crystallizes a New Entry Point into the UPR
Volume 26, Issue 1, Pages e2 (January 2018)
Insect Odorant Receptors: Channeling Scent
Volume 19, Issue 8, Pages (August 2011)
Volume 22, Issue 2, Pages (February 2014)
Discovery of New GPCR Biology: One Receptor Structure at a Time
AMPK and SNF1: Snuffing Out Stress
Volume 121, Issue 5, Pages (June 2005)
Volume 9, Issue 1, Pages (January 2016)
Volume 23, Issue 9, Pages (September 2015)
David Rodríguez, José Brea, María Isabel Loza, Jens Carlsson  Structure 
Hippo Signaling Goes Long Range
Chris Neale, Henry D. Herce, Régis Pomès, Angel E. García 
Volume 16, Issue 11, Pages (November 2008)
Arvin C. Dar, Michael S. Lopez, Kevan M. Shokat  Chemistry & Biology 
Volume 153, Issue 7, Pages (June 2013)
Intracellular Signaling
Volume 17, Issue 10, Pages (October 2009)
Sticking It to Cancer with Molecular Glue for SHP2
Two Pathways Mediate Interdomain Allosteric Regulation in Pin1
Volume 22, Issue 1, Pages (January 2014)
Novel designer receptors to probe GPCR signaling and physiology
Volume 127, Issue 7, Pages (December 2006)
Toward a Structural Understanding of Arf Family:Effector Specificity
Conformational Ensembles in GPCR Activation
Fig. 5 Active-state hallmarks of US28 bound to CX3CL1.
Fiona H. Marshall  Trends in Biochemical Sciences 
Peter Man-Un Ung, Rayees Rahman, Avner Schlessinger 
Matthew T. Eddy, Tatiana Didenko, Raymond C. Stevens, Kurt Wüthrich 
A Molecular View of Anti-ErbB Monoclonal Antibody Therapy
Volume 20, Issue 5, Pages (May 2012)
Presentation transcript:

How Ligands Illuminate GPCR Molecular Pharmacology Daniel Wacker, Raymond C. Stevens, Bryan L. Roth  Cell  Volume 170, Issue 3, Pages 414-427 (July 2017) DOI: 10.1016/j.cell.2017.07.009 Copyright © 2017 Elsevier Inc. Terms and Conditions

Figure 1 Different Ligand-Stabilized GPCR Conformations Cause Binding and Activation of Distinct Signal Transducers, including G Proteins and Arrestins Left: crystal structure of β2AR (light blue cartoon) coupled to Gαs (blue), Gβ (orange), Gγ (green) heterotrimer (PDB: 3SN6 [Rasmussen et al., 2011b]) illustrates G protein-mediated signaling. Upon heterotrimer activation, subunits dissociate, and Gα modulates second messenger production such as cAMP production through Gαs-mediated activation of adenylyl cyclase. Gβγ modulates separate Gα-independent downstream signaling networks such as ion channels, phospholipases, and receptor kinases. Right: crystal structure of rhodopsin (light blue cartoon) coupled to β-arrestin (salmon) (PDB: 4ZWJ [Kang et al., 2015]) illustrates arrestin-mediated effects such as receptor internalization or activation of kinase signaling networks. Cell 2017 170, 414-427DOI: (10.1016/j.cell.2017.07.009) Copyright © 2017 Elsevier Inc. Terms and Conditions

Figure 2 GPCRome-wide Targets of Approved and Marketed Medications and How Ligands Uncover Unknown GPCR Physiology toward Potential Therapeutic Applications (A) Sphere size corresponds to number of approved drugs for highlighted therapeutic GPCR target with antagonists, agonists, and negative allosteric modulators shown in red, green, and blue, respectively. Phylogenetic tree of the GPCRome highlights the small fraction of GPCRs that are currently targeted by approved medications. (B) Representative examples and their structures are shown for compounds used to identify previously unknown pharmacology at various receptors. Phylogenetic tree of the GPCRome highlights the diversity of GPCRs identified as off-targets. Cell 2017 170, 414-427DOI: (10.1016/j.cell.2017.07.009) Copyright © 2017 Elsevier Inc. Terms and Conditions

Figure 3 Molecular and Structural Pharmacology Extend the Ternary Complex Model for Quantitative Description of Drug Action at GPCRs Several ligand-bound inactive receptor states (R′L, R″L, etc.) and ligand-bound active receptor states (R∗1L, R∗2L, etc.), as well as ternary complex structures of ligand- and effector-bound active receptor states (R∗GL, R∗AL) (PDB: 3SN6 [Rasmussen et al., 2011b]; PDB: 4ZWJ [Kang et al., 2015]), have been structurally characterized by X-ray crystallography. Distinct conformational characteristics such as the sodium-binding site of the A2AAR (PDB: 4EIY [Liu et al., 2012b]), the ionic lock of a nanobody stabilized β2AR (PDB: 5JQH [Staus et al., 2016]), the PIF motif of the 5-HT2B receptor (PDB: 4IB4 [Wacker et al., 2013], PDB: 3NY8 [Wacker et al., 2010]), and the NPxxY motif of a nanobody-bound β2AR (PDB: 3NY8 [Wacker et al., 2010], PDB: 3P0G [Rasmussen et al., 2011a]) highlight diverse GPCR activation states. Cell 2017 170, 414-427DOI: (10.1016/j.cell.2017.07.009) Copyright © 2017 Elsevier Inc. Terms and Conditions

Figure 4 Crystal Structures of Different GPCR-Ligand Complexes Highlight the Diverse Locations of Ligand-Binding Sites Ligands are shown as stick models with transparent surfaces, and receptors are shown in cartoon representation in light blue. Complexes show retinal-bound RHO, LY2119620-bound CHRM2, sodium-bound ADORA2A, ergotamine-bound HTR2B, CCR2-RA-[R]-bound CCR2, MK-0893-bound GCGR, CP-376395-bound CRHR1, and BPTU-bound P2RY1. Cell 2017 170, 414-427DOI: (10.1016/j.cell.2017.07.009) Copyright © 2017 Elsevier Inc. Terms and Conditions

Figure 5 Computational Approaches Generate Novel Tool Compounds for GPCRs As shown here, the “pickpocketing” approach identifies GPCRs with potentially related ligand-binding properties according to ligand contact strength informed pocket alignment. Similar ligand-binding properties between the Neuropeptide S receptor (NPS) and the orphan GPCR GPR37L1 identified the NPS receptor ligand SHA68 as a novel ligand to interrogate GPR37L1 function. Data schematized according to Ngo et al. (2017). Cell 2017 170, 414-427DOI: (10.1016/j.cell.2017.07.009) Copyright © 2017 Elsevier Inc. Terms and Conditions

Cell 2017 170, 414-427DOI: (10.1016/j.cell.2017.07.009) Copyright © 2017 Elsevier Inc. Terms and Conditions